These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36111424)

  • 1. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
    Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
    Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours.
    Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
    Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
    Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
    Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
    Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
    Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors.
    Homps M; Soyer P; Coriat R; Dermine S; Pellat A; Fuks D; Marchese U; Terris B; Groussin L; Dohan A; Barat M
    Eur J Endocrinol; 2023 Oct; 189(4):476-484. PubMed ID: 37787635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.
    Liang W; Yang P; Huang R; Xu L; Wang J; Liu W; Zhang L; Wan D; Huang Q; Lu Y; Kuang Y; Niu T
    Clin Cancer Res; 2019 Jan; 25(2):584-594. PubMed ID: 30397175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.
    Gu D; Hu Y; Ding H; Wei J; Chen K; Liu H; Zeng M; Tian J
    Eur Radiol; 2019 Dec; 29(12):6880-6890. PubMed ID: 31227882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
    Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
    Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CT-based radiomics in grade 1-2 pancreatic neuroendocrine tumors.
    Heo S; Park HJ; Kim HJ; Kim JH; Park SY; Kim KW; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
    Cancer Imaging; 2024 Feb; 24(1):28. PubMed ID: 38395973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics.
    Ma M; Gu W; Liang Y; Han X; Zhang M; Xu M; Gao H; Tang W; Huang D
    J Transl Med; 2024 Aug; 22(1):768. PubMed ID: 39143624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
    Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
    Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
    Deng PZ; Zhao BG; Huang XH; Xu TF; Chen ZJ; Wei QF; Liu XY; Guo YQ; Yuan SG; Liao WJ
    World J Gastroenterol; 2022 Aug; 28(31):4376-4389. PubMed ID: 36159012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.
    Li X; Zhang N; Hu C; Lin Y; Li J; Li Z; Cui E; Shi L; Zhuang X; Li J; Lu J; Wang Y; Liu R; Yuan C; Lin H; He J; Ke D; Tang S; Zou Y; He B; Sun C; Chen M; Huang B; Mao R; Feng ST
    EClinicalMedicine; 2023 Feb; 56():101805. PubMed ID: 36618894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Computed Tomography Radiomics Signature with Progression-free Survival in Neuroblastoma Patients.
    Wang H; Li T; Xie M; Si J; Qin J; Yang Y; Zhang L; Ding H; Chen X; He L
    Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):e639-e647. PubMed ID: 37349199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prediction for lauren type of gastric cancer: A radiomics nomogram analysis based on CT images and clinical features.
    Sun Z; Jin L; Zhang S; Duan S; Xing W; Hu S
    J Xray Sci Technol; 2021; 29(4):675-686. PubMed ID: 34024809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
    Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.